000			03772nam a22003615i 4500
999			_c81202 _d81202 _x1
001			81202
003			ES-MaUEC
005			20230202102800.0
007			cr nn 008mamaa
008			150821s2015 xxu| s |||| 0|eng d
020			_a9781493925438
024	7		_a10.1007/978-1-4939-2543-8 _2doi
040			_dES-MaUEC
050		4	_aTP248.65.P76 _bB563 2015
245	1	0	_aBiobetters : _bProtein Engineering to Approach the Curative _cedited by Amy Rosenberg, Barthélemy Demeule.
260			_aNew York _bSpringer International Publishing _c2015
300			_a1 recurso en línea (XV, 378 p.) _b50 ilustraciones, 22 ilustraciones en color
336			_aTexto (visual) _btxt _2rdacontent
337			_aelectrónico _bc _2rdamedia
338			_arecurso electrónico _bcr _2rdacarrier
490	0		_aAAPS Advances in the Pharmaceutical Sciences Series _x2210-7371 _v19
505	0		_aIntroduction -- Targeting glucocerebrosidase to macrophages for effective treatment of patients with Gaucher disease: setting the paradigm of a "fit for purpose" approach to enzyme replacement therapy -- Challenges of Enzyme Replacement Therapy: Poor tissue distribution in lysosomal diseases using Pompe disease as a model -- Muscle targeting -- Blood-Brain Barrier Targeting of Therapeutic Lysosomal Enzymes -- Novel Methods for Addressing Immunogenicity in Therapeutic Enzymes -- Structure of monoclonal antibodies -- Prediction of aggregation in vivo by studies of therapeutic proteins in human plasma -- Effect of Hydrolytic Degradation on the In Vivo Properties of Monoclonal Antibodies -- Oxidation of proteins in the in-vivo environment: what we know; what we need to study and potential mitigation strategies -- Molecular assessment: balancing affinity, PK and manufacturability -- Perspectives on engineering biobetter therapeutic proteins with greater stability in inflammatory environments -- Antibody-like molecules designed for superior targeting and pharmacokinetics -- Alternative protein scaffolds as novel biotherapeutics -- Current strategies for pharmacokinetic optimization -- Biosimilar and Biobetter Scenarios for the US and Europe: What Should We Expect? -- Regulatory considerations for approval of biobetter products.
520			_aOver the last few decades, biopharmaceuticals have transformed many areas of healthcare and have given hope and extended the lives of many patients. Curative treatments, however, remain elusive in most cases. This book describes strategies to develop improved versions of biopharmaceuticals o bridge the gap between existing therapies and curative therapies. With an aim to stimulate research and development in a wide array of therapeutic areas, diverse topics are covered, including the following: tissue specific targeting of enzyme replacement therapies; the development of novel protein structures with the potential to improve upon critical attributes of current monoclonal antibodies; the modification of current monoclonal antibody designs to improve their in vivo stability; and finally, the economic and regulatory considerations for the development of biobetters.
650		7	_2embne _aProteínas _9139861
700	1		_aRosenberg, Amy _eeditor literario _993499 _0Local
700	1		_aDemeule, Barthélemy _eeditor literario _993500 _0Local
856	4	0	_uhttps://go.openathens.net/redirector/universidadeuropea.es?url=https://link.springer.com/book/10.1007/978-1-4939-2543-8 _zAcceso a este recurso digital (usuarios Universidad Europea de Madrid)
907			_a.b12897929 _b10-10-17 _c18-01-16
942			_2lcc _cLE
945			_aTP248.65.P76 B563 2015 EB _g1 _ieBOOK _j0 _lmae _o- _pEUR0.00 _q- _r- _sb _t15 _u0 _v0 _w0 _x0 _y.i11567545 _z06-04-17
988			_aEBSPRINGER
998			_am _a_alco _a_vill _b - - _cm _dz _e- _feng _gxxu _h0